Wegovy and NHS tier 3 weight management: what does it actually mean?

What is a tier 3 weight management service, and why does Wegovy sit there?

The NHS organises weight management support into tiers. Tier 1 covers public health campaigns and community resources. Tier 2 is structured lifestyle support, often group-based diet and activity programmes delivered in primary care. Tier 3 is where specialist input begins: a multidisciplinary team that typically includes a specialist nurse, dietitian, physiotherapist, and access to psychological support, all coordinating a patient's care over months or years. Tier 4 is bariatric surgery and its surrounding clinical infrastructure.

When NICE published TA875, recommending Wegovy for weight management in adults, the committee concluded that the medicine should be used within this kind of intensive support structure, not as a standalone prescription. The reasoning is straightforward: the trial evidence that underpins the recommendation (including the STEP 1 study, published in the New England Journal of Medicine, which showed around 15% average weight reduction over 68 weeks) combined behavioural support with the medicine. NICE also capped NHS use at two years. So tier 3 is not just an administrative label; it reflects a clinical philosophy that the medicine works best as part of a broader programme.

The practical consequence is a bottleneck. Tier 3 services are commissioned by NHS Integrated Care Boards, and provision is uneven across England. Scotland, Wales and Northern Ireland each have their own frameworks with different thresholds. A patient in one region might wait 12 to 18 months for a first appointment; in another, a service may not exist locally at all.

Who qualifies for Wegovy through the NHS tier 3 route?

NICE's recommendation sets out specific criteria. Adults need a BMI of 35 or above, plus at least one weight-related comorbidity, conditions such as type 2 diabetes, high blood pressure, obstructive sleep apnoea, cardiovascular disease, or dyslipidaemia. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds are 2.5 kg/m² lower throughout, in line with NHS England's weight management medicines guidance. If fewer than 5% body weight is lost after six months on the maintenance dose, the clinical team should consider stopping treatment.

These are not the same thresholds that apply to private prescribing. The licensed eligibility for Wegovy is broader: adults with a BMI of 30 or above, or 27 or above with a qualifying weight-related condition. Private prescribers work to the licensed criteria and their own clinical judgement, which is why people who fall between the licensed threshold and the NICE NHS threshold sometimes find private treatment accessible when the NHS route is not open to them yet.

A question our prescribers hear most weeks is whether someone can get a private prescription to use alongside NHS tier 3 support, or to bridge a waiting list gap. Clinically, that conversation belongs with the tier 3 team and the private prescriber together; it is never something to arrange without both sides knowing.

What are the practical differences between NHS tier 3 and a private regulated prescription?

Both routes require a clinical assessment before any prescription is issued. That part is non-negotiable for a prescription-only medicine. The differences are in speed, wraparound support structure, and cost.

Through NHS tier 3, treatment is free at the point of use and delivered within a multidisciplinary framework. The trade-off is time: referral, assessment, and the programme itself take months, often much longer. Through a GPhC-registered private pharmacy, the assessment happens quickly, at nume, a GPhC-registered Independent Prescriber reviews each consultation the same day, with ID and live weight verification built into the process. Treatment, once approved, is dispatched the same day for orders placed before midday, arriving by tracked DPD delivery the next working day. The cost of private treatment is borne by the patient; a transparent overview of what that includes is on our Wegovy pricing page.

Neither route is automatically better. For someone who qualifies for tier 3 and can access it promptly, the NHS programme offers a level of wraparound support that is hard to replicate privately. For someone who does not meet the NHS criteria today, or who is looking at a multi-year wait, a regulated private service is a legitimate, legal alternative, provided the prescriber is satisfied they are clinically suitable. You can explore the full range of treatment options we offer at our weight loss treatments page.

What should you know about Wegovy's side effect profile before starting?

Whether accessed through tier 3 or privately, the medicine is the same and so is its side effect profile. Gastrointestinal effects are the most common: nausea, loose stools, constipation, indigestion, and sometimes vomiting are all reported, most often in the first few weeks after starting or after a dose increase, and if you want to know what to expect at a specific point in that adjustment period, our guide to what day 3 on Wegovy feels like walks through the experience in detail. They typically settle as the body adjusts, though not always quickly. Staying well hydrated matters, as does eating smaller portions and avoiding foods that already upset your stomach.

More serious but less common effects to be aware of include gallbladder problems and, separately, acute pancreatitis. Seek urgent medical attention for severe, persistent stomach pain that spreads to the back, with or without vomiting. The MHRA and NHS medicines guidance on semaglutide list the full set of side effects and when to contact a doctor. Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for anyone under 18. If you are unsure whether any existing condition or medicine you take affects suitability, a prescriber will go through this carefully at the consultation stage, that review exists precisely to catch these things before treatment begins. Patients also sometimes ask about timing flexibility around their weekly injection day, and our page on whether you can take Wegovy a day earlier addresses that question clearly.

You can read more about how semaglutide works at the semaglutide overview page, and for broader background on the Wegovy injection, our Wegovy information page covers the full picture. If you have questions about supply and sourcing, the Wegovy supplier page explains how licensed UK stock reaches patients. Our about us page sets out how nume's clinical team is structured, and you can learn more about our lead prescriber at Mostafa Damghani's profile.

If you think private treatment may be right for you, check your eligibility with a free consultation, there is no obligation, and a real prescriber reviews every response.